Topic: idiopathic pulmonary fibrosis
Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.
Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.
Samumed CEO Osman Kibar discusses regenerative medicine, drugging the Wnt pathway and his company's unorthodox journey.
Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.
The deal gives Gilead access to all of Galapagos’ current and future programs outside of Europe.
Lung Therapeutics has raised a $36 million series C round to take a treatment for a serious complication of pneumonia through phase 2 studies.
AstraZeneca tapped BenevolentAI to help bring artificial intelligence and machine learning to its drug discovery projects aimed at CKD and IPF.
The series C sets Galecto up to power into late-phase development despite Bristol-Myers Squibb passing up the chance to buy it out.
Roivant Sciences’ spinout machine keeps turning with the launch of the lung-focused Respivant Sciences, with tech and staff from Patara Pharma.
Pliant Therapeutics has raised a healthy $62 million series B to help fund its proof of concept tests across a range of scarring diseases.